FDA-cleared profile

BIOGRAPH One

Siemens Healthineers AG · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))

Authorized purpose: BIOGRAPH One with syngo MR XB10 combines metabolic or physiologic PET information with MR anatomy, MR-based attenuation correction, fused alignment, and support for treatment planning and interventions.

Clinical role
MRI acquisition, reconstruction, review, and release-specific workflow support.
Images and patients
PET/SPECT/Nuclear Medicine · Multi-region
Key limitation
Keep in mind: Depending on the region of interest, contrast agents may be used. The MR system may also be used for imaging during interventional procedures and radiation therapy planning.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: BIOGRAPH One with syngo MR XB10 combines metabolic or physiologic PET information with MR anatomy, MR-based attenuation correction, fused alignment, and support for treatment planning and interventions.
  • Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Multi-region Input: Depending on the region of interest, contrast agents may be used. The PET images and measures the distribution of PET radiopharmaceuticals in humans.
  • Who uses it?Intended users: Healthcare professionals familiar with and responsible for the acquisition and post processing of magnetic resonance images.
  • What does the software produce?Output: MRI diagnostic images; PET images and measures of the distribution of PET radiopharmaceuticals; radiation-free attenuation correction maps and fused MR and PET images.
  • What is its most important limitation?Key limitation: Depending on the region of interest, contrast agents may be used. The MR system may also be used for imaging during interventional procedures and radiation therapy planning.

Clinical takeaway. Clinical role: BIOGRAPH One with syngo MR XB10 combines metabolic or physiologic PET information with MR anatomy, MR-based attenuation correction, fused alignment, and support for treatment planning and interventions.

Evidence takeaway. Evidence from the reviewed source record: K253023 reports nonclinical PET, MR, attenuation-correction, fusion, image-quality, system, software, and sample-image validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
BIOGRAPH One with syngo MR XB10 combines metabolic or physiologic PET information with MR anatomy, MR-based attenuation correction, fused alignment, and support for treatment planning and interventions.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
MRI acquisition, reconstruction, review, and release-specific workflow support.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Depending on the region of interest, contrast agents may be used. The PET images and measures the distribution of PET radiopharmaceuticals in humans.
  • Exact FDA submission
  • Checked 2026-09-19

The packet directly identifies contrast agents and PET radiopharmaceuticals; it does not state the current MRI-signal-only input value.

Output and clinician action
MRI diagnostic images; PET images and measures of the distribution of PET radiopharmaceuticals; radiation-free attenuation correction maps and fused MR and PET images.
  • Exact FDA submission
  • Checked 2026-09-19

The direct FDA indication describes MRI and PET images, attenuation-correction maps, and fused MR/PET images rather than the current generic reconstruction and workflow outputs.

Care setting
Hospital and outpatient MRI departments operating the cleared field strength, coils, protocols, and accessories.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Healthcare professionals familiar with and responsible for the acquisition and post processing of magnetic resonance images.
  • Exact FDA submission
  • Checked 2026-09-19

This replaces the current MRI-technologist wording with the packet's direct user statement.

Limitations
Depending on the region of interest, contrast agents may be used. The MR system may also be used for imaging during interventional procedures and radiation therapy planning.
  • Exact FDA submission
  • Checked 2026-09-19

This uses only the packet's stated conditions and uses; the current field-strength, coil, population, and optional-feature limits are not stated in the exact text.

Evidence summary
K253023 reports nonclinical PET, MR, attenuation-correction, fusion, image-quality, system, software, and sample-image validation.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K253023 reports nonclinical PET, MR, attenuation-correction, fusion, image-quality, system, software, and sample-image validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K253023 FDA performance package for BIOGRAPH One

  • DesignManufacturer nonclinical integrated PET/MR system, software, and sample-image verification
  • PopulationBroad integrated PET and MR diagnostic, planning, and interventional applications
  • Scopeexact submission
  • Tested versionBIOGRAPH One with syngo MR XB10
  • IndependenceSponsor or vendor study

K253023

Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K253023 by exact submission identifier. This does not exclude product-family or later safety information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Depending on the region of interest, contrast agents may be used. The PET images and measures the distribution of PET radiopharmaceuticals in humans.

    Scope: Exact FDA submission. The packet directly identifies contrast agents and PET radiopharmaceuticals; it does not state the current MRI-signal-only input value.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K253023: BIOGRAPH One

  2. Routing

    Source context, not route validation: Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K253023: BIOGRAPH One · Siemens BIOGRAPH One PET/MR

  3. AI processing

    Source context, not route validation: Installed MRI hardware and release-specific scanner software with licensed coils, sequences, and options.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K253023: BIOGRAPH One · Siemens BIOGRAPH One PET/MR

  4. Returned objects

    Source context, not route validation: MRI diagnostic images; PET images and measures of the distribution of PET radiopharmaceuticals; radiation-free attenuation correction maps and fused MR and PET images.

    Scope: Exact FDA submission. The direct FDA indication describes MRI and PET images, attenuation-correction maps, and fused MR/PET images rather than the current generic reconstruction and workflow outputs.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K253023: BIOGRAPH One

  5. Viewer/worklist/report

    Unresolved route: MRI diagnostic images; PET images and measures of the distribution of PET radiopharmaceuticals; radiation-free attenuation correction maps and fused MR and PET images.

    Scope: Exact FDA submission. The direct FDA indication describes MRI and PET images, attenuation-correction maps, and fused MR/PET images rather than the current generic reconstruction and workflow outputs.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K253023: BIOGRAPH One

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed MRI hardware and release-specific scanner software with licensed coils, sequences, and options.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Training
Only qualified mri technologists and physicians trained in magnetic resonance imaging. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Field strength, coil, sequence, anatomy, population, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K253023 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Field strength, coil, sequence, anatomy, population, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Field strength, coil, sequence, anatomy, population, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253023
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
PET/SPECT/Nuclear Medicine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The FDA indications identify MRI and PET; SPECT and the broader nuclear-medicine label in the current value are not stated in this packet. Controlled directory display reconciled from exact FDA wording: Magnetic Resonance Imaging (MRI) and PET. -> PET/SPECT/Nuclear Medicine.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-01-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA K253023: BIOGRAPH One

    U.S. Food and Drug Administration - Published 2026-01-15 - Accessed 2026-09-19

    Scope: purpose, anatomy, modality, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Siemens BIOGRAPH One PET/MR

    Siemens Healthineers - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  8. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K253023 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K254001

VERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)

Spectrum Dynamics Medical, Ltd.

Authorized purpose: VERITON CT 300/400 Series combines SPECT and CT for detection, localization, diagnosis, staging, restaging, organ-function assessment, therapy planning, guidance, and monitoring. Optional VERITAS.AI applies locked noise-reduction models to reconstructed SPECT images.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2026-01-13
FDA-cleared K243919

Voxel Dosimetry (00859873006226)

Hermes Medical Solutions AB

Authorized purpose: Voxel Dosimetry 3.1 calculates voxel-level absorbed-dose maps from nuclear-medicine images acquired after administration of FDA-approved therapeutic radiopharmaceuticals and supports single-time-point or time-series workflows.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-07-30
FDA-cleared K251528

syngo.via MI Workflows; Scenium; syngo MBF

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-07-03
FDA-cleared K251153

Aurora

GE Medical Systems Israel

Authorized purpose: Aurora is a SPECT/CT system for nuclear-medicine uptake imaging, standalone CT, anatomical localization, attenuation correction, diagnosis, staging, therapy planning, guidance, and monitoring. K251153 adds deep-learning kidney segmentation to dynamic renal scintigraphy.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-06-12

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history